BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer

BioNTech (BNTX) PT Lowered to $95 at TD Cowen

March 21, 2024 10:29 AM EDT

TD Cowen analyst Yaron Werber lowered the price target on BioNTech (NASDAQ: BNTX) to $95.00 (from $101.00) while maintaining a Market Perform rating.

The analyst comments "1.5B in Q4 Comirnaty sales missed consensus 1.8B due to write-downs from PFE & waning demand for COVID-19 boosters. FY24 revs... More

Canaccord Genuity Reviews BioNTech (BNTX) Post Earnings

March 21, 2024 7:29 AM EDT

Canaccord Genuity analyst William Maughan reiterated a Buy rating and $171.00 price target on BioNTech (NASDAQ: BNTX).

The analyst comments "Shares of BNTX are down 8% (-1% NBI) today after BioNTech presented FY23/4Q23 results. FY23 revenue of 3.8B was roughly in line with previous guidance of 4B, while FY24 guidance was updated to 2.5-3.1B (prev. ~3B). Both of those updates are incrementally below previous expectations, which... More

BioNTech (BNTX) PT Lowered to $123 at BMO Capital

March 21, 2024 6:31 AM EDT

BMO Capital analyst Etzer Darout lowered the price target on BioNTech (NASDAQ: BNTX) to $123.00 (from $127.00) while maintaining a Outperform rating.

The analyst comments "BNTX reported FY23 revenues of 3.8B vs. our 4.3B and FY24 revenue guidance of 2.53.1B vs. our 3.1B. While BNTX's financial... More

BioNTech (BNTX) PT Lowered to $91 at Goldman Sachs

March 21, 2024 4:48 AM EDT

Goldman Sachs analyst Chris Shibutani lowered the price target on BioNTech (NASDAQ: BNTX) to $91.00 (from $100.00) while maintaining a Neutral rating.

The analyst comments "BNTX reported 4Q23 earnings with Comirnaty (COVID-19 vaccine) sales coming in below expectations (1.48bn vs GS/Visible Alpha Consensus Data... More

JPMorgan Continues to See 2024 AS an 'execution year' for BioNTech (BNTX)

March 20, 2024 2:37 PM EDT

JPMorgan analyst Jessica Fye reiterated a Neutral rating and {REMOVEPT} price target on BioNTech (NASDAQ: BNTX)

The analyst comments "We continue to view 2024 as an execution year for BNTX with an aim to set the company up to achieve its longer-term goals (e.g., targeting... More

Moderna (MRNA) Trades Lower in Sympathy with BioNTech (BNTX)

March 20, 2024 7:09 AM EDT

Moderna (NASDAQ: MRNA) Trades Lower in Sympathy with BioNTech SE (NASDAQ: BNTX)

BioNTech -5.5% After EPS Misses ConsensusModerna -2%... More